Drug-eluting stents: a comprehensive appraisal

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• Percutaneous coronary interventions, including angioplasty and stenting, have transformed cardiovascular disease management.
• Long-term stent use faces challenges from in-stent restenosis and stent thrombosis.
• Drug-eluting stents (DES) were developed to overcome the significant problem of restenosis.

Purpose of the Study:

• To review the evolution and efficacy of coronary stents, particularly drug-eluting stents (DES).
• To discuss the advantages of DES over bare metal stents in various patient populations.
• To explore current and future advancements in stent technology for improved clinical outcomes.

Main Methods:

• Review of randomized trials comparing DES with bare metal stents.
• Analysis of clinical data on stent thrombosis and restenosis rates.
• Discussion of emerging stent technologies, including newer drug-eluting platforms and antibody-coated stents.

Main Results:

• DES demonstrate superior efficacy compared to bare metal stents in elective PCI, acute coronary syndromes, and diabetic patients.
• While dual-antiplatelet therapy reduced stent thrombosis, restenosis remains a concern addressed by DES.
• Newer generation DES with various drugs (everolimus, zotarolimus, tacrolimus) and improved platforms show enhanced performance.

Conclusions:

• Drug-eluting stents represent a significant advancement in managing coronary artery disease, offering improved outcomes over bare metal stents.
• While effective, the use of DES in venous bypass graft disease requires further investigation.
• Future stent developments, including antibody-coated stents, hold promise for further reducing restenosis through enhanced endothelialization.